OR WAIT null SECS
© 2022 MJH Life Sciences and Contemporary Pediatrics. All rights reserved.
© 2022 MJH Life Sciences™ and Contemporary Pediatrics. All rights reserved.
July 05, 2022
The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.